Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy

Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial

Study Objective: To evaluate the efficacy and safety of Xihuang Capsules prevention of recurrence in patients with hepatocellular carcinoma after hepatectomy.

Study Design: The study was A Multicenter, Randomized, Controlled, Open-Label, Parallel-Group Clinical Trial. Patients will be randomly assigned to Xihuang Capsules group or the control group by the proportion of 2: 1.

The total sample size: 1000 cases. Study Process: The study is divided into three phases: the screening phase, treatment phase, follow-up phase.To complete screening in two weeks, patients who fit the criteria were randomly assigned to Xihuang Capsules group or the control group.In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2g,bid), Continuously taking to cancer recurrence or death.Control group was not received Xihuang Capsules. In the first month to three years after treatment, Conducting visits for once every three months,to evaluate the efficacy and safety with hepatocellular carcinoma recurrence rate in the three years after hepatectomy as the primary outcome. When entering the follow-up phase, Keeping in touch with patients withdrew from the study for a clinic or telephone follow-up every three months.

From signing informed consent till the end of the study, inspecting the adverse events and concomitant medications for all subjects in each visit.

Study Overview

• Status: Unknown
• Conditions: Hepatocellular Carcinoma
• Intervention / Treatment: Drug: Xihuang Capsules

• Study Type: Interventional
• Enrollment (Anticipated): 1000
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Shuqun Cheng, Ph.D; Phone Number: 021-65564166

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200438
      • Recruiting
      • Eastern Hepatobiliary Surgical Hospital
      • Contact: Shuqun Cheng, Ph.D; Phone Number: 021-65564166

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age: 20-70 years old;
2. Gender: male or female;
3. clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients;
4. The expected survival> 3 months;
5. Child-Pugh grade in A-level;
6. KPS score with 50-100 points;

7. In two weeks after hepatectomy for R0 resection surgery. Preoperative must meet the following criteria:

   • BCLC stage of 0-B;
   • conform to the indications of hepatectomy;
   • Viable tumor resection confirmed by two highly qualified surgical doctors;
   • No other surgical contraindications.
8. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment;
9. Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment;
10. All patients must be prohibited donation during the treatment process and in 28 days after treatment;
11. In addition to the subjects, prohibitting other people taking this product.
12. patients have a good understanding and could coordinate with investigators for the trial.
13. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.

Exclusion Criteria:

1. Because of suffering from any serious illness,laboratory abnormalities or mental abnormalities,the patient is unable to sign an informed consent form;
2. patients with medical abnormalities may result in that the trial could not be evaluated or have security risks;
3. persons who are unable to take oral drugs.
4. coagulation dysfunction;
5. HIV, syphilis-infected persons;
6. persons who have a serious heart, liver and renal failure;
7. persons who are known to allergic to the drug or any component of the drug;
8. persons who are received experimental therapy in 28 days before the first treatment;
9. persons who are received radiotherapy or other surgery(including of the other local surgery for cancer treatment,eg. TACE) in addition to hepatectomy in 14 days before the first treatment;
10. lactating or pregnant women;
11. patients in the reproductive period are unwilling or unable to contraception;
12. persons with poor medication compliance;
13. The researchers considered unsuitable selected patients.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: the control group; Patients in Control group were not received Xihuang Capsules.
Experimental: Xihuang Capsules group; Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.	Drug: Xihuang Capsules; In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.; Other Names: Wangbang Pharmaceutical Xihuang Capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hepatocellular carcinoma recurrence rate in the three years after hepatectomy	Diagnostic criteria for hepatocellular carcinoma recurrence: refer to Chinese Anti-Cancer Association Professional Committee of hepatocellular carcinoma developed diagnostic criteria for primary hepatocellular carcinoma belong to Guangzhou standard in 2001. Once new or suspected place nature lesions within liver were found by B-ultrasonography examination,we should do CT, MRI or PET-CT review, in order to confirm the diagnosis. If imaging is positive, diagnosing hepatocellular carcinoma(dominant) recurrence after treatment; if imaging is negative, but AFP values> 400μg/L or ongoing elevated AFP values, diagnosing hepatocellular carcinoma occult recurrence after treatment.	in the three years after hepatectomy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hepatocellular carcinoma recurrence rate in a year after hepatectomy		in a year after hepatectomy
Relapse free survival (RFS)	RFS is defined as from date of randomization until the date of first documented tumor recurrence or date of death from any cause, whichever came first.	up to 5 years
Hepatocellular carcinoma survival rate in a year or three years after hepatectomy		in a year or three years after hepatectomy
Overall survival(OS)	OS is defined as from date of randomization until the date of documented death from any cause.	up to 5 years
Improvement in quality of life in a year or three years after hepatectomy	Using Karnofsky-Performance-Status score: Evaluation Methods: Comparison of symptom scores before and after the treatment. Markedly: increasing by more than 20 points after treatment compared to before treatment; Effective: increasing by more than 10 points after treatment compared to before treatment; Stable: increasing by less than 10 points or no change after treatment compared to before treatment; Invalid: decrease after treatment than before treatment.	in a year or three years after hepatectomy
number of participants with improvement of clinical symptoms, Such as flank pain, bloating, fatigue, anorexia and other syndromes of traditional Chinese Medicine.	Evaluation index : according to clinical observations, TCM symptoms are divided into 4 levels: (0) no symptoms, (1) mild, (2) moderate, (3)severe, Recording treatment according to symptoms. Evaluation methods: comparison of symptom total integral before and after the treatment (before treatment / after treatment) Markedly: symptom disappeared, or symptom integral reduce ≥ 2/3; Effective: symptom alleviative, integral is reduced≥1/3，≤2/3; Invalid: symptom is not alleviated or reduced<1/3.	participants will be followed for the duration of study, an expected average of 3 months.
The incidence of adverse reaction.	Classification according to the Common Terminology Criteria Adverse Events Version 4.0(CTCAE v4.0).	up to 5 years

Collaborators and Investigators

• Sponsor: Shuqun Cheng
• Investigators: Principal Investigator: Shuqun Cheng, Ph.D, Eastern Hepatobiliary Surgical Hospital

Study record dates

Study Major Dates

• Study Start: June 1, 2014
• Primary Completion (Anticipated): July 1, 2019
• Study Completion (Anticipated): December 1, 2019

Study Registration Dates

• First Submitted: February 12, 2015
• First Submitted That Met QC Criteria: March 22, 2015
• First Posted (Estimate): March 26, 2015

Study Record Updates

• Last Update Posted (Estimate): March 26, 2015
• Last Update Submitted That Met QC Criteria: March 22, 2015
• Last Verified: February 1, 2015

More Information

Terms related to this study

• Keywords: Recurrence; hepatocellular carcinoma; hepatectomy; Xihuang Capsules
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Disease Attributes; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Recurrence
• Other Study ID Numbers: SCheng